Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 9,869,200 | 8,930,700 | 7,574,400 | 6,205,700 | 4,162,800 |
| Cost of Goods | 1,262,200 | 1,080,300 | 904,200 | 736,300 | 547,800 |
| Gross Profit | 8,607,000 | 7,850,400 | 6,670,200 | 5,469,400 | 3,615,000 |
| Operating Expenses | 4,775,200 | 3,543,300 | 3,888,300 | 2,613,400 | 2,418,300 |
| Operating Income | 3,832,000 | 4,307,400 | 2,782,100 | 2,856,300 | 1,197,500 |
| Interest Expense | 44,100 | 54,800 | 61,500 | 58,200 | 58,500 |
| Other Income | 591,900 | -20,200 | 9,800 | 318,800 | 255,900 |
| Pre-tax Income | 4,379,800 | 4,232,400 | 2,730,400 | 3,116,900 | 1,394,900 |
| Income Tax | 760,200 | 910,400 | 388,300 | 405,200 | 218,100 |
| Net Income Continuous | 3,619,600 | 3,322,000 | 2,342,100 | 2,711,700 | 1,176,800 |
| Net Income | $3,619,600 | $3,322,000 | $2,342,100 | $2,711,700 | $1,176,800 |
| EPS Basic Total Ops | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 |
| EPS Basic Continuous Ops | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 |
| EPS Diluted Total Ops | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 |
| EPS Diluted Continuous Ops | 13.89 | 12.82 | 9.01 | 10.30 | 4.51 |
| EPS Diluted Before Non-Recurring Items | 13.80 | 13.28 | 11.87 | 9.03 | 4.29 |
| EBITDA(a) | $4,013,301 | $4,455,700 | $2,907,700 | $2,965,800 | $1,304,400 |